BMEZ:NYE-BlackRock Health Sciences Trust II (USD)

COMMON STOCK | |

Last Closing

USD 15.4

Change

+0.04 (+0.26)%

Market Cap

USD 1.64B

Volume

0.41M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-01 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
TBB AT&T Inc

+0.21 (+0.91%)

USD 141.83B
PFH Prudential Financial Inc 4.125..

+0.17 (+0.86%)

USD 45.49B
PRS Prudential Financial Inc

+0.20 (+0.81%)

USD 44.13B
ALL-PB The Allstate Corporation

+0.20 (+0.78%)

USD 32.88B
SOJC Southern Co

+0.14 (+0.58%)

USD 23.25B
AIO Virtus AllianzGI Artificial In..

+0.12 (+0.56%)

USD 16.20B
AIZN Assurant Inc

+0.20 (+0.97%)

USD 9.38B
RZB Reinsurance Group of America I..

+0.19 (+0.76%)

USD 8.84B
PCG-PA Pacific Gas and Electric Compa..

+0.06 (+0.27%)

USD 6.04B
PCG-PB Pacific Gas and Electric Compa..

-0.70 (-3.17%)

USD 5.84B

ETFs Containing BMEZ

PCEF Invesco CEF Income Compos.. 2.97 % 0.50 %

+0.09 (+0.48%)

USD 0.75B

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.12% N/A N/A 63% D
Dividend Return 4.30% N/A N/A 88% B+
Total Return 9.42% N/A N/A 72% C
Trailing 12 Months  
Capital Gain -5.98% N/A N/A 23% F
Dividend Return 6.75% N/A N/A 81% B-
Total Return 0.77% N/A N/A 29% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.50% N/A N/A 14% F
Dividend Return -0.62% N/A N/A 25% F
Total Return 5.89% N/A N/A 85% B
Risk Return Profile  
Volatility (Standard Deviation) 24.17% N/A N/A 43% F
Risk Adjusted Return -2.55% N/A N/A 28% F
Market Capitalization 1.64B N/A N/A 61% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike